AI Model Predicts EGFR Mutations From Pathology Slides in Lung Cancer
July 9, 2025
An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.